hameln pharma ApS: Financial statements 2025
CVR: 39720213
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
hameln pharma ApS (CVR 39720213) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 10,300,176 and a net result of DKK 8,050,599 compared with DKK 5,288,671 the year before. That is an increase of 50.2% compared with the year before. Equity in the 2025 report amounted to DKK 20,334,774. The solvency ratio was 83.4%.
- Gross Profit
- DKK 10,300,176
- Profit/Loss
- DKK 8,050,599
- Equity
- DKK 20,334,774
- Total Assets
- DKK 24,368,598
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 10.3 mio. | 8.1 mio. | 20.3 mio. | 0 |
| 2024 | - | 6.9 mio. | 5.3 mio. | 12.3 mio. | 0 |
| 2023 | - | 3.1 mio. | 2.3 mio. | 7.4 mio. | 0 |
| 2022 | - | 2.6 mio. | 1.9 mio. | 5 mio. | 0 |
| 2021 | - | 1.9 mio. | 1.4 mio. | 3.2 mio. | 0 |
Official annual report
How creditworthy is hameln pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Hameln pharma ApS has won the tender "Amgros 2026 1.601.a" issued by Amgros I/S worth 331,750,548 DKK.
Hameln pharma ApS has won the tender "Amgros 2026 2.1302.b" issued by Amgros I/S worth 161,990,275 DKK.
Hameln pharma ApS has won the tender "Amgros 2026 1.615.b" issued by Amgros I/S worth 48,195,968 DKK.
Hameln pharma ApS has won the tender "Amgros 2026 1.201.a" issued by Amgros I/S worth 286,787,957 DKK.
Hameln pharma ApS has published its annual report for 2024. Gross profit came to DKK 6,856,814, and the net result was DKK 5,288,671.
About hameln pharma ApS
hameln pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Frank Jahrand and Stephen Allen Watkin. The company is owned by hameln pharma gmbh. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 10,300,176 and a net result of DKK 8,050,599 compared with DKK 5,288,671 the year before. Equity in the 2025 report amounted to DKK 20,334,774.